Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 28, 2026

Jim Cramer says Warren Buffett is wrong about investors being addicted to 'gambling' — they're addicted to the S&P 500

View original at finance.yahoo.com
Jim Cramer says Warren Buffett is wrong about investors being addicted to 'gambling' — they're addicted to the S&P 500 Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The denigration of individual stock investing has made markets more casino-like; if individual stock picking had been respected, speculation would be lower

    60% confidence

  • Markets have never felt this speculative and people have never been in a more gambling mood

    60% confidence

  • Current markets resemble a church with a casino attached, and the casino side has grown very crowded while the speculative instruments have become progressively more attractive

    60% confidence

  • Investors have been trained to love ETFs indiscriminately regardless of what kind they are

    60% confidence

  • Investors are addicted to buying the S&P 500 regardless of market conditions, not to gambling on individual stocks

    60% confidence

  • Speculation is not limited to gambling on individual stocks — it is a growing issue across all levels of the market including instruments traditionally considered safe

    60% confidence

  • Zero days to expiration (0DTE) options are not investing or speculating — they are pure gambling because they involve placing quick wagers on tiny price moves over just a few hours

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Jim Cramer says Warren Buffett is wrong about investors being addicted to 'gambling' — they're addicted to the S&P 500 — Source | Via News | ViaNews Market